Company intelligence / Profile preview
Cullinan Therapeutics
Cambridge, Massachusetts, United Statescullinantherapeutics.com ↗
- Ownership
- Public · CGEM
- Development stage
- Phase 2
01
Overview
Cullinan’s lead asset zipalertinib met its primary endpoint in a pivotal Phase 2b trial for NSCLC patients with EGFR exon20ins mutations who have received prior therapy. The safety profile was consistent with previous data presentations (~40% objective response rate). An FDA approval application submission is planned for H2 2025. CLN‑619 continues dose escalation/expansion in multiple solid tumor cohorts; CLN‑978 advancing into SLE trials; other assets progressing through early clinical phases or IND-enabling studies[8][9][10].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Bispecific T cell engagersSmall moleculesProtein degradersTCR-based constructs[7][8][10]
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Taiho Pharmaceutical Co., Ltd.: Partnership on development/commercialization of zipalertinib [5].
Beyond the preview
Go deeper on Cullinan Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cullinan Therapeutics.